Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma

Immunotherapy regimens have shown success in subsets of cancer patients; however, their efficacy against pancreatic ductal adenocarcinoma (PDA) remain unclear. Previously, we demonstrated the potential of TAB004, a monoclonal antibody targeting the unique tumor-associated form of MUC1 (tMUC1) in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Dréau, Didier, Moore, Laura Jeffords, Wu, Mike, Roy, Lopa Das, Dillion, Lloye, Porter, Travis, Puri, Rahul, Momin, Noor, Wittrup, K. Dane, Mukherjee, Pinku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503151/
https://www.ncbi.nlm.nih.gov/pubmed/31114758
http://dx.doi.org/10.3389/fonc.2019.00330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503151/
https://www.ncbi.nlm.nih.gov/pubmed/31114758
http://dx.doi.org/10.3389/fonc.2019.00330

Ejemplares similares